US20060094608A1 - Warming and nonirritating lubricant compositions and method of comparing irritation - Google Patents

Warming and nonirritating lubricant compositions and method of comparing irritation Download PDF

Info

Publication number
US20060094608A1
US20060094608A1 US11/299,884 US29988405A US2006094608A1 US 20060094608 A1 US20060094608 A1 US 20060094608A1 US 29988405 A US29988405 A US 29988405A US 2006094608 A1 US2006094608 A1 US 2006094608A1
Authority
US
United States
Prior art keywords
compositions
composition
temperature
water
warming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/299,884
Inventor
Nawaz Ahmad
Ying Sun
Shun Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29269095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060094608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US11/299,884 priority Critical patent/US20060094608A1/en
Publication of US20060094608A1 publication Critical patent/US20060094608A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/14—Topical contraceptives and spermacides

Definitions

  • This invention relates to personal lubricant compositions that are warming and nonirritating when applied to the skin or mucous membranes, especially the vaginal or oral mucosa.
  • the compositions of this invention are substantially anhydrous and contain one or more polyhydric alcohol.
  • This invention also relates to the method that can be used to test and compare the irritation of the compositions of this invention and other personal lubricants known to the art.
  • compositions range from jellies to liquids to vaginal suppositories and vary from being aqueous to oils to silicone based.
  • the majority of the compositions actually used today are aqueous jellies or aqueous liquids.
  • Most personal lubricants known and available for use today are cold to touch, a feeling that can be uncomfortable.
  • compositions are known to the trade or described in the literature that claim to impart a warming sensation upon application to the skin or mucosa. Some of these compositions use plant extracts which are irritating to the skin and mucous membranes and give a feeling or perception of warmth by virtue of their irritant action. Others claim to enhance blood flow in order to cause tissue warming. Still others are alleged to work on the principle of freezing point depression and are well suited for heating in a microwave or cooling in a refrigerator. There is one cosmetic composition rendered self-heating by inclusion of compound containing a boron-to-boron linkage, which reacts exothermally with water.
  • compositions known to the trade contains plant extracts such as Cinnamon cassia (Cinnamon), Zingiber officinalis (Ginger), Mint, Sandalwood, Orange and Clove, which are all known to be skin irritants.
  • plant extracts such as Cinnamon cassia (Cinnamon), Zingiber officinalis (Ginger), Mint, Sandalwood, Orange and Clove, which are all known to be skin irritants.
  • Such a composition has the disadvantage of causing irritation to the mucosa, which can be problematic in relation to the vaginal or oral mucosa as irritation may promote the growth of unwanted bacteria and cause infection.
  • WETTM Heating Massage Oil distributed by International, Valencia, Calif.
  • Retinyl Palmitate (Vitamin A Palmitate), Prunus amygdalis (Prunes), Amara (Almond), Persica gratissima (Avacado Oil), Macdamia ternifulia Seed Oil, Kakeri Nut Oil, Helianthus annus (hybrid Sunflower), Cannabis sativa (Hemp) Seed Oil and Aloe vera.
  • Most of these ingredients are known irritants that are not suitable for use on mucous membranes.
  • compositions are actually “warm”, or at a relatively higher temperature than the ambient temperature of the product or the surrounding environment.
  • U.S. Pat. No. 4,110,426, entitled “Method of Treating Skin and Hair with a Self Heated Cosmetic, Organic Boron-Oxygen-Boron Compounds” describes non-aqueous compositions such as shaving creams, that are rendered self-heating by including therein a compound containing at least one boron-oxygen-boron linkage, such as triethoxyboroxine.
  • the boron-containing compound reacts exothermally with water or other protic material to increase temperature.
  • compositions are not suitable for vaginal or oral use due to the potential toxicity of boron-containing compounds to the human reproductive system (Fail P A, et al., general, reproductive, developmental, and endocrine toxicity of boronated compounds , Reprod toxicol 12: 1, 1-18, January-February, 1998).
  • Physical energy forms have been utilized to enhance material transport across a membrane for therapeutic purposes.
  • energy forms include electricity, ultrasound and thermal energy (e.g., heat-assisted drug delivery), (reviewed by Sun, in “Skin Absorption Enhancement by Physical Means: Heat, Ultrasound, and Electricity”, Transdermal and Topical Drug Delivery Systems , Interpharm Press, Inc., 1997, pages 327-355).
  • Local heating of a drug delivery system or formulation, as well as the skin or mucosal tissues not only increases thermodynamic energy of drug molecules and membrane permeability to facilitate drug movement across a barrier membrane, it improves blood circulation in the tissue to expedite drug removal from the local tissue into the systemic circulation. Both processes leads to an enhanced absorption of the drug.
  • Experimental evidence demonstrates that low-level heating (i.e., a tissue temperature of less than about 42° C.) significantly enhances percutaneous drug absorption.
  • U.S. Pat. No. 5,658,583 describes a heat-generating apparatus for improved dermal permeation of pharmaceuticals.
  • the apparatus includes a thin drug formulation reservoir and a heat-generating chamber of oxidation reaction separated by a non-permeable wall.
  • the drug formulation reservoir houses a predetermined amount of a formulation containing pharmaceutical agents.
  • the heat-generating/temperature-regulating chamber includes a heat-generating medium consisting of carbon, iron, water and/or salt which is activated upon contact with oxygen in the air.
  • a complicated heating device such as this is not suitable for use in the vaginal or oral cavity for obvious safety concerns.
  • U.S. Pat. No. 6,019,782 describes disposable thermal body pads with heat generation via an oxidation reaction intended for relieving menstrual pain when applied onto the abdominal skin.
  • ThermaCare® Air-Activated Heatwraps Menstrual Cramp Relief patches manufactured by Procter & Gamble (Cincinnati, Ohio).
  • Procter & Gamble Cincinnati, Ohio
  • compositions and methods of this invention relate to warming lubricant compositions that are non-toxic and non-irritating and that can be used as personal lubricants designed to come into contact with the skin or mucosa.
  • the compositions of this invention increase in temperature or generate warmth. This has a soothing effect on the tissues to which these compositions are applied.
  • compositions of this invention may be applied to the skin or mucous membranes, preferably the vaginal or oral mucosa.
  • the compositions of this invention are preferably substantially anhydrous and preferably contain at least one polyhydric alcohol.
  • compositions of this invention when the polyhydric alcohols contained in the compositions of this invention come into contact with water or body moisture in humans, they react with the ambient water molecules to cause an increase in temperature or generate warmth, thus having a soothing effect on the tissues to which these compositions are applied.
  • compositions of this invention containing such polyhydric alcohols have been found to be non-irritating. In fact, these compositions are very mild to the skin and mucous membranes.
  • the compositions of this invention are soothing when applied to oral mucous membranes and may function to relieve minor irritation of the mouth and throat.
  • compositions of this invention may also be used as a vehicle to solubilize otherwise insoluble drugs, including, but not limited to, antifungals, antibacterials, antivirals, analgesics, anti-inflammatory steroids, contraceptives, local anaesthetics, hormones and the like.
  • compositions of this invention also preferably contain an insulating agent which functions to preserve the temperature increase by maintaining the heat within the composition after it has been applied to the skin or mucosa. More preferably, honey may be utilized as an insulating agent.
  • FIG. 1 is a graph depicting the % viable Epiderm cells vs Exposure Time using the composition of Example 1.
  • FIG. 2 is a graph depicting the % viable Epiderm cells vs Exposure Time using the composition of Example 2.
  • FIG. 3 is a graph depicting the % viable Epiderm cells vs Exposure Time using a State-of-the-Art non-irritating Product (K-Y Liquid@)
  • FIG. 4 is a graph depicting the % viable Epiderm cells vs Exposure Time using a State-of-the-Art warming Product (Prosensual®)
  • FIG. 5 is a graph comparing the Lubricity vs Time (Seconds) of the composition of Example 1 and three leading Personal Lubricants on the market.
  • compositions of this invention are substantially anhydrous, preferably containing less than about 20% water, more preferably containing less than about 5% water and, most preferably, containing less than about 3% water.
  • the compositions of this invention contain at least one polyhydric alochol, and more preferably, two polyhydric alcohols.
  • the polyhydric alcohol portion of the compositions of this invention one or more polyhydric alcohols such as alkylene glycols and others selected from the following group: glycerin, propylene glycol, butylene glycol, hexalene glycol or polyethylene glycol of various molecular weight and the like and/or combination thereof.
  • compositions of this invention contain a polyethylene glycol; most preferably, the polyethylene glycol may be selected from the following group: polyethylene glycol 400 or polyethylene glycol 300.
  • the compositions of this invention should contain polyhydric alcohols in an amount from about 80% to about 98% by weight of the composition.
  • compositions of this invention preferably also contain an insulating agent.
  • the insulating agent should be honey or esters of isopropyl alcohol and saturated high molecular weight fatty acids such as myristic or palmitic acid, e.g., isopropyl myristate and isopropyl palmitate.
  • the insulating agent should be present in the compositions of this invention in an amount of from about 1% to about 5% by weight of the composition.
  • compositions of this invention are unexpectedly self-preserving and may not require a preservative.
  • a preservative may be added to impart an additional guarantee against microbial growth.
  • a preservative may be selected from preservatives known to those of skill in the art, including, but not limited to, one or more of the following: methylparaben, benzoic acid, sorbic acid, gallic acid, propylparaben or the like.
  • the preservative may be present in the compositions of this invention in an amount from about 0.01% to about 0.75% by weight of the composition.
  • compositions of this invention may also preferably contain an ester. More preferably, the ester is a fatty acid ester. Most preferably, the ester may include, but is not limited to: isopropyl stearate, isopropyl myristate, isopropyl palmitate, isopropyl laurate and the like. Most preferably, the ester is isopropyl myristate.
  • compositions of this invention may contain one or more water-soluble cellulose-derived polymers, gums, chitosans or the like. Such polymers contribute to the viscosity and bioadhesiveness of the compositions of this invention.
  • cellulose-derived polymers are hydroxyalkylcellulose polymers. More preferably, the hydroxyalkylcellulose polymer is hydroxypropylcellulose or Klucel®, available commercially from Hercules Incorporated, Wilmington, Del.
  • the polyhydric alcohols used in the compositions of this invention are theorized to be useful as warming and heat-generating agents.
  • Honey functions as an insulating agent, protecting the compositions from becoming too cold.
  • the ester preferably a fatty acid ester, functions as an emollient and lubricant.
  • the cellulose polymer is useful as a viscosity building agent.
  • the compositions of this invention are unique in that they lubricate, warm and soothe the tissues of the user, especially the oral and vaginal mucous membranes, without conveying a feeling of cold. Moreover, they are smooth and lubricating.
  • compositions of this invention may be a liquid, a semi-solid, or a solid depending upon the particular intended use thereof.
  • the compositions of this invention may also be formulated into soft or hard gelatin capsules, suppositories and impregnated into fabrics or polymers.
  • compositions of this invention may be used as personal lubricants which convey a feeling of warmth.
  • the feeling of warmth generated by the compositions of this invention is soothing to the skin or mucous membranes where they are applied.
  • the compositions of the invention also possess a sweet and pleasant taste, which is of particular benefit when these compositions are used orally.
  • compositions of this invention may also be used as personal moisturizers, which convey a feeling of warmth when applied to vaginal or oral mucosa.
  • compositions of this invention may also be used as a vehicle to deliver medication or other treatment agents to the biomembranes including, but not limited to, hormones, antimicrobial or antifungal agents and the like.
  • the antifungal agents is preferably an azole or imidazole, including but not limited to, miconazole, econazole, terconazole, saperconazole, itraconazole, butaconazole, clotrimazole, tioconazole, fluconazole and ketoconazole, vericonazole, fenticonazole, sertaconazole, posaconazole, bifonazole, oxiconazole, sulconazole, elubiol, vorconazole, isoconazole, flutrimazole and their pharmaceutically acceptable salts and the like.
  • antifungal agents may include an allylamine or one from other chemical families, including but not limited to, ternafine, naftifine, amorolfine, butenafine, ciclopirox, griseofulvin, undecyclenic acid, haloprogin, tolnaftate, nystatin, iodine, rilopirox, BAY 108888, purpuromycin and their pharmaceutically acceptable salts.
  • compositions for vulvovaginal use containing one or more antibiotics.
  • the antibiotic may be chosen from the group including, but not limited to, metronidazole, clindamycin, timidazole, ornidazole, secnidazole, refaximin, trospectomycin, purpuromycin and their pharmaceutically acceptable salts and the like.
  • compositions of this invention include compositions for vulvovaginal use containing one or more antiviral agents.
  • Antiviral agents may preferably include, but are not limited to, immunomodulators, more preferably imiquimod, its derivatives, podofilox, podophyllin, interferon alpha, reticolos, cidofovir, nonoxynol-9 and their pharmaceutically acceptable salts and the like.
  • compositions of this invention are compositions that include one or more spermicides.
  • the spermicides may preferably include, but are not limited to, nonoxynol-9, octoxynol-9, dodecaethyleneglycol monolaurate, Laureth 10S, and Methoxypolyoxyethyleneglycol 550 Laurate and the like.
  • compositions of this invention are compositions containing antimicrobial agents.
  • the antimicrobial agents may preferably include, but are not limited to, chlorohexidine gluconate, sodium polystyrene sulfonate, sodium cellulose sulfate, silver particles of micro- and sub-micrometer sizes, silver salts and other antibacterial agents known to the art.
  • compositions of this invention are compositions that may include local anesthetics.
  • the local anesthetics may preferably include, but are not limited to, benzocaine, lidocaine, dibucaine, benzyl alcohol, camphor, resorcinol, menthol and diphenylhydramine hydrochloride and the like.
  • compositions of the invention may also include plant extracts such as aloe, witch hazel, chamomile, hydrogenated soy oil and colloidal oatmeal, vitamins such as vitamin A, D or E and corticosteroids such as hydrocortisone acetate.
  • plant extracts such as aloe, witch hazel, chamomile, hydrogenated soy oil and colloidal oatmeal
  • vitamins such as vitamin A, D or E
  • corticosteroids such as hydrocortisone acetate.
  • compositions for vulvovaginal use containing one or more hormones for treating a decrease in estrogen secretion in the woman in need of estrogen replacement such as women with vaginal atrophy.
  • the hormones may preferably include, but are not limited to, estrogen selected from the group consisting of estradiol, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enanthate, conjugated estrogen, estriol, estrone, estrone sulfate, ethinyl estradiol, estrofurate, quinestrol and mestranol.
  • compositions and methods of this invention include compositions for vulvovaginal use containing one or more analgesics and/or nonsteroidal anti-inflammatory agents for treating dysmenorrhea or mentrual cramping.
  • the analgesics and nonsteroidal anti-inflammatory agents may preferably include, but are not limited to, aspirin, ibuprofen, indomethacin, phenylbutazone, bromfenac, fenamate, sulindac, nabumetone, ketorolac, and naproxen and the like.
  • compositions for oral and vulvovaginal use relates to a method of enhancing the absorption of active agents from the applied compositions into the mucosal membrane by increasing the composition and mucosal tissue temperature via interaction of the polyhydric alcohols in the compositions and moisture on the mucosa and subsequently released heat.
  • compositions for vulvovaginal use relate to compositions and methods for preventing and/or treating dysmenorrhea by intravaginal warming or heating.
  • the composition heats the intravaginal area to a temperature preferably between about 37° C. and about 42° C., more preferably between about 38° C. and about 41° C.
  • the compositions of invention for use in such a method may optionally contain active agents such as analgesics and nonsteroidal anti-inflammatory agents for dysmenorrhea treatment.
  • the composition of the invention may be administered directly into the vagina by an applicator, or be impregnated into vaginal devices such as tampon for intravaginal applications.
  • compositions of this invention may be manufactured as a coating of a tampon, or dispersing throughout the absorbent tampon material, or enclosed inside as a core of a tampon.
  • the compositions of this invention for the warming tampon for preventing and/or treating dysmenorrhea preferably include a mixture of polyethylene glycols of various molecular weights produced by The Dow Chemical Company (Midland, Mich.) under the trade names of CARBOWAX SENTRY PEG 300 NF, CARBOWAX SENTRY PEG 400 NF, CARBOWAX SENTRY PEG 600 NF, CARBOWAX SENTRY PEG 900 NF, CARBOWAX SENTRY PEG 1000 NF, CARBOWAX SENTRY PEG 1450 NF, CARBOWAX SENTRY PEG 3500 NF, CARBOWAX SENTRY PEG 4000 NF, CARBOWAX SENTRY PEG 4600 NF, and CARBOWAX
  • compositions of this invention for dysmenorrhea prophylaxis and treatment may contain one or more water-soluble cellulose-derived polymers and gums that form gels around the polyhydric alcohols such as glycerin, propylene glycol and polyethylene glycols thus reducing the dissolution of the polyhydric alcohols, prolonging the solvation heat release, and regulating the elevated temperature in the preferred temperature range.
  • polyhydric alcohols such as glycerin, propylene glycol and polyethylene glycols
  • This invention also relates to a method of determining and comparing relative amounts of irritation caused by particular sources using the EpiDermTM Skin Model Assay as described in Example 1, such as compositions applied to skin or mucosal cells.
  • Example 1 exemplifies the use of the method of this invention.
  • EpiDermTM Skin Model assay uses the epithelial cells derived from human skin as target cells and is commercially available from the MatTek Corporation. This assay is described in Berridge, M. V., et al. (1996) The Biochemical and Cellular Basis of Cell Proliferation Assays That Use Tetrazolium Salts . Biochemica 4: 14-19.
  • the test materials are applied directly to the epithelial cell culture surface. This test has not previously been used for determining toxicity of test materials. The toxicity of the test material is evaluated on the basis of relative tissue viability vs time. The actual Tissue Viability is determined by NAD(P)H-dependent microsomal enzyme reduction of MTT in control and test article treated cultures.
  • the negative control used in this assay was deionized water and the positive control was Triton X-100.
  • the exposed cell cultures were incubated for 4, 8, 16 and 24 hours and assayed for reduction of MTT.
  • the data is presented below in FIGS. 1 through 4 in the form of Relative Survival (relative MTT reduction) versus Exposure Time. Products with higher relative survival rates are less toxic or less irritating while the ones with lower survival rates are more toxic or irritating.
  • FIGS. 1 through 4 summarize the results of Epiderm Skin. Model Bioassay. The data is plotted as % Viable Cells vs the Exposure Time ranging from 4 to 24 hours.
  • FIGS. 1 and 2 represent the results for two compositions of this invention, Composition 1 and Composition 2 respectively.
  • FIG. 3 represents the results of K-Y® Liquid that is an established personal lubricant on the market. K-Y® Liquid is established as safe and nonirritating in animal and human testing and long-term human use history. Results for K-Y® Liquid showed 100.3% viable cells after 24 hour of exposure ( FIG. 3 ).
  • Example 1 of the invention ( FIG. 1 ) and Example 2 of the invention ( FIG. 2 ) showed 91.1% and 96.9% viable cells respectively.
  • FIG. 4 shows the results of a warming composition known to the trade. This product uses plant materials like cinnamon, clove, ginger cloves and orange and others for a warming sensation. The results show only 37.6% viable cells after 24 hours of exposure to this product. This indicates that such compositions will be irritating to the skin and mucous membranes. Compositions 1 and 2 of this invention, with 91.1% and 96.9% viable cells respectively, will be practically nonirritating. Positive control (Triton X-100) has only 22.4% viable cells at the 8-hour interval.
  • compositions of this invention are anhydrous and contain one or more polyhydric alcohol.
  • the polyhydric alcohols used in the compositions of this invention When combined with water, the polyhydric alcohols used in the compositions of this invention generate an increase in temperature that has a soothing effect on the tissues these compositions are applied.
  • the compositions of the invention interact with the moisture of the vaginal or oral mucosa, thereby increasing the temperature or generating feeling of warmth.
  • the calculated rise in temperature for Composition 1, based on the rise in temperature and the % w/w quantity of each individual ingredient in the composition was 10.875° F.
  • the actual recorded temperature rise for Composition 1. was 12.5° F. which is 1.625° F. higher than expected which indicates that there is an unexpected increase in temperature resulting from the combination of ingredients.
  • compositions of this invention On contact with moisture or water the heat of solution is responsible for the warming action of the compositions of this invention. There is a concern that accidental contamination with water or prolonged exposure to excessive moisture, the warming capacity of the product may be adversely effected.
  • water was added to compositions of this invention varying from about 1% to about 10% as outlined in Table 2 below. The contents were thoroughly mixed and the samples were allowed to stay at room temperature for 24 hour following which the generation of warmth was determined as outlined in the following paragraph. The results show that rise in temperature is proportionately decreased depending on the quantity of water added but there is still an 8.5° F. increase in temperature at about 10% water addition.
  • the lubricity of various marketed personal lubricants was determined over a period of 300 seconds (5 minutes).
  • the lubricity data disclosed in this patent indicates that K-Y Liquid® lubricant had a higher lubricity and was longer lasting during the 300 seconds test period than the competitive products.
  • the lubricity data set forth in U.S. Pat. No. 6,139,848 has a negative ( ⁇ ) sign during the “push” and positive (+) sign during the “pull” phase of the experiment.
  • compositions of this invention were tested using the lubricity test set foth in U.S. Pat. No. 6,129,848. However, the test duration was successfully extended to 16 minutes (960 seconds) and the data was treated to “curve-fit” to eliminate the negative ( ⁇ ) sign.
  • the lubricity data for the composition 1 of this invention is compared with the data for K-Y Liquid® in FIG. 5 . The data indicate that Composition 1 of this invention has a higher lubricity as compare to K-Y Liquid® and that Composition 1 maintains the high lubricity for an extended period of 16 minutes (960 minutes) and is therefore longer lasting.
  • compositions of this invention were made as follows: first, propylene glycol and glycerin were mixed. A preservative and the insulating agent were then added to the mixture in the same container. The mixture was then heated to from about 35° C. to about 45° C. to completely dissolve the preservative. The mixture was then cooled.
  • Composition 1 Propylene Glycol 50.00% Glycerin 45.00% Honey 5.00%
  • Composition 2 Propylene Glycol 50.00% Glycerin 20.00% Isopropyl Myristate 27.00% Polysorbate 60 3.00%
  • Composition 3 Propylene Glycol 95.00% Honey 5.00%
  • Composition 4 Propylene Glycol 50.00% Glycerin 20.00% Isopropyl Myristate 29.50% Klucel HF 0.50%
  • Composition 5 Propylene Glycol 99.50% Klucel HF 0.50%
  • Composition 6 Propylene Glycol 49.80% Glycerin 45.00% Honey 5.00% Preservative 0.20%
  • Composition 7 Miconazole Nitrate 2.00% Propylene Glycol 49.80% Glycerin 43.00% Honey 5.00% Preservative 0.20%
  • Composition 8 Fluconazole 2.00% Propylene Glycol 49.80% Glycerin 43.00% Honey 5.00% Preservative 0.20%
  • Composition 9 Metronidazole 3.00% Propylene Glycol 49.80% Glycerin 42.00% Honey 5.00% Preservative 0.20%

Abstract

This invention relates to substantially anhydrous warming, non-toxic and nonirritating lubricating compositions containing polyhydric alcohols and an insulating agent. The invention also relates to methods of using such compositions for lubrication, administration of active ingredients and for preventing or treating dysmenorrhea.

Description

    FIELD OF THE INVENTION
  • This invention relates to personal lubricant compositions that are warming and nonirritating when applied to the skin or mucous membranes, especially the vaginal or oral mucosa. The compositions of this invention are substantially anhydrous and contain one or more polyhydric alcohol. This invention also relates to the method that can be used to test and compare the irritation of the compositions of this invention and other personal lubricants known to the art.
    • BACKGROUND OF THE INVENTION
  • In the field of personal lubricants and medicaments applied to mucosal membranes, from time to time attempts have been made to overcome the problem of the perception of cold. When an individual applies personal lubricant or medicament such compositions to internal mucosal membranes, often an individual experiences an uncomfortable, cold feeling due to the difference in temperature between the body and the ambient temperature.
  • An appreciable number of personal lubricant compositions are known to the art. These compositions range from jellies to liquids to vaginal suppositories and vary from being aqueous to oils to silicone based. The majority of the compositions actually used today are aqueous jellies or aqueous liquids. Almost all personal lubricants known and available for use today are cold to touch, a feeling that can be uncomfortable.
  • A number of compositions are known to the trade or described in the literature that claim to impart a warming sensation upon application to the skin or mucosa. Some of these compositions use plant extracts which are irritating to the skin and mucous membranes and give a feeling or perception of warmth by virtue of their irritant action. Others claim to enhance blood flow in order to cause tissue warming. Still others are alleged to work on the principle of freezing point depression and are well suited for heating in a microwave or cooling in a refrigerator. There is one cosmetic composition rendered self-heating by inclusion of compound containing a boron-to-boron linkage, which reacts exothermally with water.
  • One example of a composition known to the trade, Prosensual™, distributed by Lexie Trading, Inc., Fairlaw, N.J., contains plant extracts such as Cinnamon cassia (Cinnamon), Zingiber officinalis (Ginger), Mint, Sandalwood, Orange and Clove, which are all known to be skin irritants. Such a composition has the disadvantage of causing irritation to the mucosa, which can be problematic in relation to the vaginal or oral mucosa as irritation may promote the growth of unwanted bacteria and cause infection.
  • Another current composition, WET™ Heating Massage Oil, distributed by International, Valencia, Calif., uses Retinyl Palmitate (Vitamin A Palmitate), Prunus amygdalis (Prunes), Amara (Almond), Persica gratissima (Avacado Oil), Macdamia ternifulia Seed Oil, Kakeri Nut Oil, Helianthus annus (hybrid Sunflower), Cannabis sativa (Hemp) Seed Oil and Aloe vera. Most of these ingredients are known irritants that are not suitable for use on mucous membranes.
  • U.S. Pat. No. 5,895,658, entitled “Delivery of L-Arginine to Cause Tissue Warming, Sustained Release of Nitric Oxide to treat effects of Diabetes, Stimulate Hair Growth and Heal Wounds,” describes a preparation for producing enhanced blood flow in tissues thus causing beneficial effects, such as warming cold tissues of hands and feet.
  • U.S. Pat. No. 5,513,629 entitled “Microwavable Heat Releasing and Absorbing Compositions and Container, Pliable Gel Comprising Humectant, Freezing Point Depressant, Gel Sealer, Polyacrylamide Absorbent, Corn Starch Binder, Mineral Oil and Plasticizers, Durability, Efficacy” describes compositions that have a high vapor points and are, therefore, suited for heating in a microwave oven or cooling in a freezer and placement in a suitable container or vinyl package, such as a hot-and-cold pack, but not for human consumption or use.
  • However, none of the foregoing compositions are actually “warm”, or at a relatively higher temperature than the ambient temperature of the product or the surrounding environment.
  • U.S. Pat. No. 4,110,426, entitled “Method of Treating Skin and Hair with a Self Heated Cosmetic, Organic Boron-Oxygen-Boron Compounds” describes non-aqueous compositions such as shaving creams, that are rendered self-heating by including therein a compound containing at least one boron-oxygen-boron linkage, such as triethoxyboroxine. The boron-containing compound reacts exothermally with water or other protic material to increase temperature. Such compositions are not suitable for vaginal or oral use due to the potential toxicity of boron-containing compounds to the human reproductive system (Fail P A, et al., general, reproductive, developmental, and endocrine toxicity of boronated compounds, Reprod toxicol 12: 1, 1-18, January-February, 1998).
  • Physical energy forms have been utilized to enhance material transport across a membrane for therapeutic purposes. Such energy forms include electricity, ultrasound and thermal energy (e.g., heat-assisted drug delivery), (reviewed by Sun, in “Skin Absorption Enhancement by Physical Means: Heat, Ultrasound, and Electricity”, Transdermal and Topical Drug Delivery Systems, Interpharm Press, Inc., 1997, pages 327-355). Local heating of a drug delivery system or formulation, as well as the skin or mucosal tissues, not only increases thermodynamic energy of drug molecules and membrane permeability to facilitate drug movement across a barrier membrane, it improves blood circulation in the tissue to expedite drug removal from the local tissue into the systemic circulation. Both processes leads to an enhanced absorption of the drug. Experimental evidence demonstrates that low-level heating (i.e., a tissue temperature of less than about 42° C.) significantly enhances percutaneous drug absorption.
  • U.S. Pat. No. 5,658,583 describes a heat-generating apparatus for improved dermal permeation of pharmaceuticals. The apparatus includes a thin drug formulation reservoir and a heat-generating chamber of oxidation reaction separated by a non-permeable wall. The drug formulation reservoir houses a predetermined amount of a formulation containing pharmaceutical agents. The heat-generating/temperature-regulating chamber includes a heat-generating medium consisting of carbon, iron, water and/or salt which is activated upon contact with oxygen in the air. However, a complicated heating device such as this is not suitable for use in the vaginal or oral cavity for obvious safety concerns.
  • Locally applied heat (such as an abdominal heating patch) has also been used to treat dysmenorrhea, or menstrual cramps, with demonstrated efficacy (Akin M D et al., Continuous low-level topical heat in the treatment of dysmenorrhea., Obstet Gynecol 97: 3, 343-9, March, 2001).
  • U.S. Pat. No. 6,019,782 describes disposable thermal body pads with heat generation via an oxidation reaction intended for relieving menstrual pain when applied onto the abdominal skin. There is currently a commercial product in the U.S. market for dysmenorrhea treatment based on abdominal heating, ThermaCare® Air-Activated Heatwraps, Menstrual Cramp Relief patches manufactured by Procter & Gamble (Cincinnati, Ohio). However, there are no products or description of internal localized heating to treat dysmenorrhea.
    • SUMMARY OF THE INVENTION
  • The compositions and methods of this invention relate to warming lubricant compositions that are non-toxic and non-irritating and that can be used as personal lubricants designed to come into contact with the skin or mucosa. When mixed with water, the compositions of this invention increase in temperature or generate warmth. This has a soothing effect on the tissues to which these compositions are applied.
  • The compositions of this invention may be applied to the skin or mucous membranes, preferably the vaginal or oral mucosa. The compositions of this invention are preferably substantially anhydrous and preferably contain at least one polyhydric alcohol.
  • We theorize that, when the polyhydric alcohols contained in the compositions of this invention come into contact with water or body moisture in humans, they react with the ambient water molecules to cause an increase in temperature or generate warmth, thus having a soothing effect on the tissues to which these compositions are applied.
  • Surprisingly, and contrary to the general belief that polyhydric alcohols in compositions are irritating to the mucosa, compositions of this invention containing such polyhydric alcohols have been found to be non-irritating. In fact, these compositions are very mild to the skin and mucous membranes. The compositions of this invention are soothing when applied to oral mucous membranes and may function to relieve minor irritation of the mouth and throat.
  • The combination of polyhydric alcohols in the compositions of this invention may also be used as a vehicle to solubilize otherwise insoluble drugs, including, but not limited to, antifungals, antibacterials, antivirals, analgesics, anti-inflammatory steroids, contraceptives, local anaesthetics, hormones and the like.
  • The compositions of this invention also preferably contain an insulating agent which functions to preserve the temperature increase by maintaining the heat within the composition after it has been applied to the skin or mucosa. More preferably, honey may be utilized as an insulating agent.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph depicting the % viable Epiderm cells vs Exposure Time using the composition of Example 1.
  • FIG. 2 is a graph depicting the % viable Epiderm cells vs Exposure Time using the composition of Example 2.
  • FIG. 3 is a graph depicting the % viable Epiderm cells vs Exposure Time using a State-of-the-Art non-irritating Product (K-Y Liquid@)
  • FIG. 4 is a graph depicting the % viable Epiderm cells vs Exposure Time using a State-of-the-Art warming Product (Prosensual®)
  • FIG. 5 is a graph comparing the Lubricity vs Time (Seconds) of the composition of Example 1 and three leading Personal Lubricants on the market.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The compositions of this invention are substantially anhydrous, preferably containing less than about 20% water, more preferably containing less than about 5% water and, most preferably, containing less than about 3% water. Preferably, the compositions of this invention contain at least one polyhydric alochol, and more preferably, two polyhydric alcohols. Preferably the polyhydric alcohol portion of the compositions of this invention one or more polyhydric alcohols such as alkylene glycols and others selected from the following group: glycerin, propylene glycol, butylene glycol, hexalene glycol or polyethylene glycol of various molecular weight and the like and/or combination thereof. More preferably, the compositions of this invention contain a polyethylene glycol; most preferably, the polyethylene glycol may be selected from the following group: polyethylene glycol 400 or polyethylene glycol 300. The compositions of this invention should contain polyhydric alcohols in an amount from about 80% to about 98% by weight of the composition.
  • The compositions of this invention preferably also contain an insulating agent. More preferably, the insulating agent should be honey or esters of isopropyl alcohol and saturated high molecular weight fatty acids such as myristic or palmitic acid, e.g., isopropyl myristate and isopropyl palmitate. The insulating agent should be present in the compositions of this invention in an amount of from about 1% to about 5% by weight of the composition.
  • The compositions of this invention are unexpectedly self-preserving and may not require a preservative. However, a preservative may be added to impart an additional guarantee against microbial growth. A preservative may be selected from preservatives known to those of skill in the art, including, but not limited to, one or more of the following: methylparaben, benzoic acid, sorbic acid, gallic acid, propylparaben or the like. The preservative may be present in the compositions of this invention in an amount from about 0.01% to about 0.75% by weight of the composition.
  • The compositions of this invention may also preferably contain an ester. More preferably, the ester is a fatty acid ester. Most preferably, the ester may include, but is not limited to: isopropyl stearate, isopropyl myristate, isopropyl palmitate, isopropyl laurate and the like. Most preferably, the ester is isopropyl myristate.
  • The compositions of this invention may contain one or more water-soluble cellulose-derived polymers, gums, chitosans or the like. Such polymers contribute to the viscosity and bioadhesiveness of the compositions of this invention. Preferably, such cellulose-derived polymers are hydroxyalkylcellulose polymers. More preferably, the hydroxyalkylcellulose polymer is hydroxypropylcellulose or Klucel®, available commercially from Hercules Incorporated, Wilmington, Del.
  • The polyhydric alcohols used in the compositions of this invention are theorized to be useful as warming and heat-generating agents. Honey functions as an insulating agent, protecting the compositions from becoming too cold. The ester, preferably a fatty acid ester, functions as an emollient and lubricant. The cellulose polymer is useful as a viscosity building agent. The compositions of this invention are unique in that they lubricate, warm and soothe the tissues of the user, especially the oral and vaginal mucous membranes, without conveying a feeling of cold. Moreover, they are smooth and lubricating.
  • The compositions of this invention may be a liquid, a semi-solid, or a solid depending upon the particular intended use thereof. The compositions of this invention may also be formulated into soft or hard gelatin capsules, suppositories and impregnated into fabrics or polymers.
  • The compositions of this invention may be used as personal lubricants which convey a feeling of warmth. The feeling of warmth generated by the compositions of this invention is soothing to the skin or mucous membranes where they are applied. The compositions of the invention also possess a sweet and pleasant taste, which is of particular benefit when these compositions are used orally.
  • The compositions of this invention may also be used as personal moisturizers, which convey a feeling of warmth when applied to vaginal or oral mucosa.
  • The compositions of this invention may also be used as a vehicle to deliver medication or other treatment agents to the biomembranes including, but not limited to, hormones, antimicrobial or antifungal agents and the like. The antifungal agents is preferably an azole or imidazole, including but not limited to, miconazole, econazole, terconazole, saperconazole, itraconazole, butaconazole, clotrimazole, tioconazole, fluconazole and ketoconazole, vericonazole, fenticonazole, sertaconazole, posaconazole, bifonazole, oxiconazole, sulconazole, elubiol, vorconazole, isoconazole, flutrimazole and their pharmaceutically acceptable salts and the like. Other antifungal agents may include an allylamine or one from other chemical families, including but not limited to, ternafine, naftifine, amorolfine, butenafine, ciclopirox, griseofulvin, undecyclenic acid, haloprogin, tolnaftate, nystatin, iodine, rilopirox, BAY 108888, purpuromycin and their pharmaceutically acceptable salts.
  • Another embodiment of the invention are compositions for vulvovaginal use containing one or more antibiotics. The antibiotic may be chosen from the group including, but not limited to, metronidazole, clindamycin, timidazole, ornidazole, secnidazole, refaximin, trospectomycin, purpuromycin and their pharmaceutically acceptable salts and the like.
  • Another embodiment of the compositions of this invention include compositions for vulvovaginal use containing one or more antiviral agents. Antiviral agents may preferably include, but are not limited to, immunomodulators, more preferably imiquimod, its derivatives, podofilox, podophyllin, interferon alpha, reticolos, cidofovir, nonoxynol-9 and their pharmaceutically acceptable salts and the like.
  • Still other embodiments of the compositions of this invention are compositions that include one or more spermicides. The spermicides may preferably include, but are not limited to, nonoxynol-9, octoxynol-9, dodecaethyleneglycol monolaurate, Laureth 10S, and Methoxypolyoxyethyleneglycol 550 Laurate and the like.
  • Still other embodiments of the compositions of this invention are compositions containing antimicrobial agents. The antimicrobial agents may preferably include, but are not limited to, chlorohexidine gluconate, sodium polystyrene sulfonate, sodium cellulose sulfate, silver particles of micro- and sub-micrometer sizes, silver salts and other antibacterial agents known to the art.
  • Yet other embodiments of the compositions of this invention are compositions that may include local anesthetics. The local anesthetics may preferably include, but are not limited to, benzocaine, lidocaine, dibucaine, benzyl alcohol, camphor, resorcinol, menthol and diphenylhydramine hydrochloride and the like.
  • Compositions of the invention may also include plant extracts such as aloe, witch hazel, chamomile, hydrogenated soy oil and colloidal oatmeal, vitamins such as vitamin A, D or E and corticosteroids such as hydrocortisone acetate.
  • Another embodiment of the compositions and methods of this invention include compositions for vulvovaginal use containing one or more hormones for treating a decrease in estrogen secretion in the woman in need of estrogen replacement such as women with vaginal atrophy. The hormones may preferably include, but are not limited to, estrogen selected from the group consisting of estradiol, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enanthate, conjugated estrogen, estriol, estrone, estrone sulfate, ethinyl estradiol, estrofurate, quinestrol and mestranol.
  • Another embodiment of the compositions and methods of this invention include compositions for vulvovaginal use containing one or more analgesics and/or nonsteroidal anti-inflammatory agents for treating dysmenorrhea or mentrual cramping. The analgesics and nonsteroidal anti-inflammatory agents may preferably include, but are not limited to, aspirin, ibuprofen, indomethacin, phenylbutazone, bromfenac, fenamate, sulindac, nabumetone, ketorolac, and naproxen and the like.
  • Yet another embodiment of the compositions and methods of this invention include compositions for oral and vulvovaginal use relates to a method of enhancing the absorption of active agents from the applied compositions into the mucosal membrane by increasing the composition and mucosal tissue temperature via interaction of the polyhydric alcohols in the compositions and moisture on the mucosa and subsequently released heat.
  • Yet another embodiment of the compositions of this invention include compositions for vulvovaginal use relates to compositions and methods for preventing and/or treating dysmenorrhea by intravaginal warming or heating. Preferably, the composition heats the intravaginal area to a temperature preferably between about 37° C. and about 42° C., more preferably between about 38° C. and about 41° C. The compositions of invention for use in such a method may optionally contain active agents such as analgesics and nonsteroidal anti-inflammatory agents for dysmenorrhea treatment. The composition of the invention may be administered directly into the vagina by an applicator, or be impregnated into vaginal devices such as tampon for intravaginal applications.
  • The compositions of this invention may be manufactured as a coating of a tampon, or dispersing throughout the absorbent tampon material, or enclosed inside as a core of a tampon. The compositions of this invention for the warming tampon for preventing and/or treating dysmenorrhea preferably include a mixture of polyethylene glycols of various molecular weights produced by The Dow Chemical Company (Midland, Mich.) under the trade names of CARBOWAX SENTRY PEG 300 NF, CARBOWAX SENTRY PEG 400 NF, CARBOWAX SENTRY PEG 600 NF, CARBOWAX SENTRY PEG 900 NF, CARBOWAX SENTRY PEG 1000 NF, CARBOWAX SENTRY PEG 1450 NF, CARBOWAX SENTRY PEG 3500 NF, CARBOWAX SENTRY PEG 4000 NF, CARBOWAX SENTRY PEG 4600 NF, and CARBOWAX SENTRY PEG 8000 NF. The compositions of this invention for dysmenorrhea prophylaxis and treatment may contain one or more water-soluble cellulose-derived polymers and gums that form gels around the polyhydric alcohols such as glycerin, propylene glycol and polyethylene glycols thus reducing the dissolution of the polyhydric alcohols, prolonging the solvation heat release, and regulating the elevated temperature in the preferred temperature range.
  • This invention also relates to a method of determining and comparing relative amounts of irritation caused by particular sources using the EpiDerm™ Skin Model Assay as described in Example 1, such as compositions applied to skin or mucosal cells. The following Example 1 exemplifies the use of the method of this invention.
    • EXAMPLE 1 EpiDerm™ Skin Model Assay to Test Irritation of Lubricants
  • The method designated as EpiDerm™ Skin Model assay uses the epithelial cells derived from human skin as target cells and is commercially available from the MatTek Corporation. This assay is described in Berridge, M. V., et al. (1996) The Biochemical and Cellular Basis of Cell Proliferation Assays That Use Tetrazolium Salts. Biochemica 4: 14-19. The test materials are applied directly to the epithelial cell culture surface. This test has not previously been used for determining toxicity of test materials. The toxicity of the test material is evaluated on the basis of relative tissue viability vs time. The actual Tissue Viability is determined by NAD(P)H-dependent microsomal enzyme reduction of MTT in control and test article treated cultures. The negative control used in this assay was deionized water and the positive control was Triton X-100. The exposed cell cultures were incubated for 4, 8, 16 and 24 hours and assayed for reduction of MTT. The data is presented below in FIGS. 1 through 4 in the form of Relative Survival (relative MTT reduction) versus Exposure Time. Products with higher relative survival rates are less toxic or less irritating while the ones with lower survival rates are more toxic or irritating.
  • FIGS. 1 through 4 summarize the results of Epiderm Skin. Model Bioassay. The data is plotted as % Viable Cells vs the Exposure Time ranging from 4 to 24 hours. FIGS. 1 and 2 represent the results for two compositions of this invention, Composition 1 and Composition 2 respectively. FIG. 3 represents the results of K-Y® Liquid that is an established personal lubricant on the market. K-Y® Liquid is established as safe and nonirritating in animal and human testing and long-term human use history. Results for K-Y® Liquid showed 100.3% viable cells after 24 hour of exposure (FIG. 3).
  • Example 1 of the invention (FIG. 1) and Example 2 of the invention (FIG. 2) showed 91.1% and 96.9% viable cells respectively. FIG. 4 shows the results of a warming composition known to the trade. This product uses plant materials like cinnamon, clove, ginger cloves and orange and others for a warming sensation. The results show only 37.6% viable cells after 24 hours of exposure to this product. This indicates that such compositions will be irritating to the skin and mucous membranes. Compositions 1 and 2 of this invention, with 91.1% and 96.9% viable cells respectively, will be practically nonirritating. Positive control (Triton X-100) has only 22.4% viable cells at the 8-hour interval.
    • EXAMPLE 2 Generation Of Warmth
  • The compositions of this invention are anhydrous and contain one or more polyhydric alcohol. When combined with water, the polyhydric alcohols used in the compositions of this invention generate an increase in temperature that has a soothing effect on the tissues these compositions are applied. In actual use the compositions of the invention interact with the moisture of the vaginal or oral mucosa, thereby increasing the temperature or generating feeling of warmth.
  • The “Generation of warmth” data summarized in Table 1 below, was generated by mixing 20 ml of each of the ingredients in Composition 1 and Composition 1 of this invention with 20 ml of water. The temperature of the product and that of water were recorded before water was added to the product. After the addition of water the mixture was mixed for two minutes and the actual temperature was recorded. Glycerin, Propylene Glycol and Honey are the ingredients in Composition 1. It is clear from Table 1. that when mixed with water the temperature of the mixture rises by 9.0° F. for Glycerin, 13.5° F. for Propylene Glycol, 17.0° F. for Polyethylene Glycol 400 and 12.5° F. for composition Example 1 of this invention. The calculated rise in temperature for Composition 1, based on the rise in temperature and the % w/w quantity of each individual ingredient in the composition was 10.875° F. The actual recorded temperature rise for Composition 1. was 12.5° F. which is 1.625° F. higher than expected which indicates that there is an unexpected increase in temperature resulting from the combination of ingredients.
    GENERATION OF WARMTH (RISE IN TEMPERATURE ° F.) DATA BY MIXING EQUAL
    QUANTITY OF EACH PRODUCT WITH WATER
    Rise in
    Average Temperature
    Temperature Expected Actual (° F.)
    of the Product Temperature Temperature Temperature (Expected
    Product Name (° F.) of Water (° F.) (° F.) (° F.) Minus Actual)
    Glycerin 69.0 71.0 70.0 79.0 9.0
    Assay
    Propylene 72.4 71.0 71.7 85.2 13.5
    Glycol
    Assay
    Honey 74.0 71.0 72.5 74.0 1.5
    K-Y Warm ® 74.0 71.0 72.5 85.0 12.5
    Isopropyl 75.0 74.1 74.5 75.2 0.7
    Myristate
    Polysorbate
    60 70.9 74.1 72.5 83.1 10.6
    Polyethylene 72.0 71.0 71.5 88.5 17.0
    Glycol 400
  • Calculated Rise in Temperature: In order to determine the expected rise in temperature from each composition, the percentage of each component in such composition was multiplied by the temperature increase generated by such component alone to obtain its expected contribution to the temperature increase. These values were added together to calculate the total expected temperature rise. These values were then compared with the actual temperature rise generated by each composition. For example, the calculated rise in temperature generated by the “K-Y Warm®” composition in the table above was found as follows and compared with the actual temperature rise to determine the unexpectedly higher generation of warmth of the composition:
    Propylene Glycol (50% of 13.5) = 6.75
    Glycerin (45% of 9.0) = 4.05
    Honey (5% of 1.5) = 0.075
    Total 10.875

    Difference: 12.5-10.875=1.625
    • EXAMPLE 3 Effect of Water Content on Generation of Warmth
  • On contact with moisture or water the heat of solution is responsible for the warming action of the compositions of this invention. There is a concern that accidental contamination with water or prolonged exposure to excessive moisture, the warming capacity of the product may be adversely effected. According to this example, water was added to compositions of this invention varying from about 1% to about 10% as outlined in Table 2 below. The contents were thoroughly mixed and the samples were allowed to stay at room temperature for 24 hour following which the generation of warmth was determined as outlined in the following paragraph. The results show that rise in temperature is proportionately decreased depending on the quantity of water added but there is still an 8.5° F. increase in temperature at about 10% water addition.
  • The results of this example are set forth in Table 2 below.
    TABLE 2
    Effect Of Water Content On Generation Of Warmth For
    K-Y Warm ®.
    Rise in
    Temperature
    Temperature Average (° F.)
    of the Temperature Expected Actual (Expected
    Sample of Water Temperature Temperature Minus
    Product Name (° F.) (° F.) (° F.) (° F.) Actual)
    No Water 73.80 70.00 71.90 83.50 11.60
    1% Water 73.90 70.00 71.95 82.20 10.25
    2% Water 72.30 70.00 71.95 81.70 9.85
    3% Water 72.30 70.00 71.15 80.40 9.25
    4% water 72.20 70.00 71.10 80.70 9.60
    5% Water 71.60 70.00 70.80 80.40 9.60
    6% Water 71.60 70.00 70.80 80.40 9.60
    7% Water 71.50 70.00 70.75 80.20 9.45
    8% Water 71.60 70.00 70.80 80.20 9.40
    9% Water 70.90 70.00 70.45 79.50 9.05
    10% Water  70.50 70.00 70.25 79.00 8.50
    • EXAMPLE 4 Perception Of Warmth In Human Use
  • A human use study was conducted with 246 subjects. The data generated by this study are summarized below in Table 2. The subjects were asked to use compositions of this invention. They were asked three questions regarding the perception of warmth while using the product, as follows:
    • 1. Does it warm on contact?
    • 2. Does it feel warm?
    • 3. Does it not feel cold?
  • The subjects were asked to register their response as Excellent, Very Good, Good, Fair and Poor. The positive responses are summarized in Table 2.
    TABLE 3
    PERCEPTION OF WARMTH IN HUMAN USE STUDY WITH 246
    HUMAN SUBJECTS USING COMPOSITION EXAMPLE 1 OF THE
    INVENTION
    QUESTION ASKED POSITIVE RESPONSE (%)
    Warms on Contact
    Excellent 25.12
    Very Good 31.88
    Good 24.64
    Total 81.64
    Feels Warm
    Excellent 30.88
    Very Good 28.92
    Good 25.98
    Total 85.78
    Does Not Feel Cold
    Excellent 54.37
    Very Good 29.61
    Good 10.19
    Total 94.53
  • As set forth in Table 3 above, 81.64% of the subjects registered a positive response that the product “warms on contact”, 85.78% subjects felt that the product “feels warm” while 94.53% subjects registered that the product “does not feel cold”.
    • EXAMPLE 4 Comparison Of Lubricity
  • Ahmad et al. in U.S. Pat. No. 6,139,848, which is hereby incorporated herein by reference, describe a method to test lubricity of various personal lubricants known to the trade. In the described test method, the lubricity of various marketed personal lubricants was determined over a period of 300 seconds (5 minutes). The lubricity data disclosed in this patent indicates that K-Y Liquid® lubricant had a higher lubricity and was longer lasting during the 300 seconds test period than the competitive products. The lubricity data set forth in U.S. Pat. No. 6,139,848 has a negative (−) sign during the “push” and positive (+) sign during the “pull” phase of the experiment. Compositions of this invention were tested using the lubricity test set foth in U.S. Pat. No. 6,129,848. However, the test duration was successfully extended to 16 minutes (960 seconds) and the data was treated to “curve-fit” to eliminate the negative (−) sign. The lubricity data for the composition 1 of this invention is compared with the data for K-Y Liquid® in FIG. 5. The data indicate that Composition 1 of this invention has a higher lubricity as compare to K-Y Liquid® and that Composition 1 maintains the high lubricity for an extended period of 16 minutes (960 minutes) and is therefore longer lasting.
    • EXAMPLES 5-9 Compositions of the Invention
  • The following compositions of this invention were made as follows: first, propylene glycol and glycerin were mixed. A preservative and the insulating agent were then added to the mixture in the same container. The mixture was then heated to from about 35° C. to about 45° C. to completely dissolve the preservative. The mixture was then cooled.
  • Composition 1:
    Propylene Glycol 50.00%
    Glycerin 45.00%
    Honey 5.00%
  • Composition 2:
    Propylene Glycol 50.00%
    Glycerin 20.00%
    Isopropyl Myristate 27.00%
    Polysorbate
    60 3.00%
  • Composition 3:
    Propylene Glycol 95.00%
    Honey 5.00%
  • Composition 4:
    Propylene Glycol 50.00%
    Glycerin 20.00%
    Isopropyl Myristate 29.50%
    Klucel HF 0.50%
  • Composition 5:
    Propylene Glycol 99.50%
    Klucel HF 0.50%
  • Composition 6:
    Propylene Glycol 49.80%
    Glycerin 45.00%
    Honey 5.00%
    Preservative 0.20%
  • Composition 7:
    Miconazole Nitrate 2.00%
    Propylene Glycol 49.80%
    Glycerin 43.00%
    Honey 5.00%
    Preservative 0.20%
  • Composition 8:
    Fluconazole 2.00%
    Propylene Glycol 49.80%
    Glycerin 43.00%
    Honey 5.00%
    Preservative 0.20%
  • Composition 9:
    Metronidazole 3.00%
    Propylene Glycol 49.80%
    Glycerin 42.00%
    Honey 5.00%
    Preservative 0.20%

Claims (9)

1. A substantially anhydrous lubricant composition comprising at least one polyhydric alcohol and an insulating agent.
2-14. (canceled)
15. A method of treating or preventing dysmenorrhea comprising applying a composition comprising from about 80% to about 98% by weight polyhydric alcohol and less than about 20% by weight water intravaginally.
16-18. (canceled)
19. A method of providing personal lubrication to a human's oral or vaginal mucosa during intercourse comprising applying to the oral or vaginal mucosa a composition comprising a substantially anhydrous lubricant composition which conveys a feeling of warmth upon application comprising at least one polyhydric alcohol.
20. A method of providing personal lubrication to a human's vaginal mucosa during intercourse comprising applying to the vaginal mucosa a composition comprising a substantially anhydrous lubricant composition which conveys a feeling of warmth upon application comprising at least one polyhydric alcohol.
21. A method according to claim 19 wherein said polyhydric alcohol is selected from the group consisting of: glycerin, alkylene glycol, polyethylene glycol and a mixture thereof.
22. A method according to claim 21 wherein said composition comprises from about 80% to about 98% by weight polyhydric alcohol
23. A method according to claim 28 wherein said composition comprises about 50% by weight propylene glycol and about 45% by weight glycerin.
US11/299,884 2002-05-01 2005-12-12 Warming and nonirritating lubricant compositions and method of comparing irritation Abandoned US20060094608A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/299,884 US20060094608A1 (en) 2002-05-01 2005-12-12 Warming and nonirritating lubricant compositions and method of comparing irritation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/137,509 US7005408B2 (en) 2002-05-01 2002-05-01 Warming and nonirritating lubricant compositions and method of comparing irritation
US11/299,884 US20060094608A1 (en) 2002-05-01 2005-12-12 Warming and nonirritating lubricant compositions and method of comparing irritation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/137,509 Division US7005408B2 (en) 2002-05-01 2002-05-01 Warming and nonirritating lubricant compositions and method of comparing irritation

Publications (1)

Publication Number Publication Date
US20060094608A1 true US20060094608A1 (en) 2006-05-04

Family

ID=29269095

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/137,509 Expired - Lifetime US7005408B2 (en) 2002-05-01 2002-05-01 Warming and nonirritating lubricant compositions and method of comparing irritation
US10/389,871 Expired - Lifetime US7285517B2 (en) 2002-05-01 2003-03-17 Warming and nonirritating lubricant compositions and method of comparing irritation
US10/390,511 Expired - Lifetime US7758887B2 (en) 2002-05-01 2003-03-17 Warming and nonirritating lubricant compositions and method of comparing irritation
US11/299,884 Abandoned US20060094608A1 (en) 2002-05-01 2005-12-12 Warming and nonirritating lubricant compositions and method of comparing irritation

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US10/137,509 Expired - Lifetime US7005408B2 (en) 2002-05-01 2002-05-01 Warming and nonirritating lubricant compositions and method of comparing irritation
US10/389,871 Expired - Lifetime US7285517B2 (en) 2002-05-01 2003-03-17 Warming and nonirritating lubricant compositions and method of comparing irritation
US10/390,511 Expired - Lifetime US7758887B2 (en) 2002-05-01 2003-03-17 Warming and nonirritating lubricant compositions and method of comparing irritation

Country Status (13)

Country Link
US (4) US7005408B2 (en)
EP (2) EP2108359B1 (en)
JP (3) JP4712377B2 (en)
KR (2) KR20110125660A (en)
AU (5) AU2003225242A1 (en)
BR (1) BRPI0309769B8 (en)
CA (1) CA2484275C (en)
DE (1) DE60328475D1 (en)
ES (3) ES2640745T3 (en)
MX (1) MXPA04010887A (en)
NZ (1) NZ588194A (en)
RU (1) RU2344808C2 (en)
WO (1) WO2003092651A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188528A1 (en) * 2005-02-23 2006-08-24 Ansell Healthcare Products Llc Spreadable warming lubricant
US20060189493A1 (en) * 2005-02-23 2006-08-24 Ansell Healthcare Products Llc Thickened spreadable warming lubricant
US20070059266A1 (en) * 2005-09-12 2007-03-15 Nawaz Ahmad Sprayable personal lubricant
US20070059250A1 (en) * 2005-09-12 2007-03-15 Nawaz Ahmad Sprayable personal lubricant
US20090107513A1 (en) * 2007-10-26 2009-04-30 Ansell Healthcare Products Llc Condom With Multifunctional Coating

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1316558B9 (en) * 2000-09-08 2005-12-07 San-Ei Gen F.F.I., Inc. Tetraphenylbacteriochlorin derivatives and compositions containing the same
US7417013B2 (en) * 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US20040185065A1 (en) * 2002-05-01 2004-09-23 Nawaz Ahmad Warming and nonirritating lubricant compositions and method of comparing irritation
US7005408B2 (en) 2002-05-01 2006-02-28 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US7695730B2 (en) * 2002-05-01 2010-04-13 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US7658941B2 (en) 2002-05-01 2010-02-09 Johnson & Johnson Consumer Companies, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US20040167039A1 (en) * 2002-05-01 2004-08-26 Nawaz Ahmad Warming and nonirritating lubricant compositions and method of comparing irritation
US7480530B2 (en) * 2003-06-30 2009-01-20 Johnson & Johnson Consumer Companies, Inc. Device for treatment of barrier membranes
US8734421B2 (en) * 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
CN100594944C (en) * 2003-10-30 2010-03-24 麦克内尔-Ppc股份有限公司 Soft surface coating composition, method for decorating soft surface and absorbent articles comprising metal-loaded nanoparticles
WO2005081952A2 (en) * 2004-02-26 2005-09-09 Church & Dwight Co., Inc. Condom with warmth imparting lubricant
US8273024B2 (en) * 2004-03-16 2012-09-25 Rita Kathleen Chew Ultrasound transmission gel
WO2005097210A1 (en) * 2004-03-26 2005-10-20 The University Of Utah Research Foundation Bioresponsive polymer system for delivery of microbicides
GB0409725D0 (en) * 2004-05-04 2004-06-09 Taylor Russell The method of manufacture and application of a chelating substance for the purpose of altering and changing the conditions in female reproductive organs
US7767215B2 (en) * 2004-06-29 2010-08-03 Mcka Llc Topical compositions for anti-aging and methods of using same
US20060003654A1 (en) * 2004-06-30 2006-01-05 Lostocco Michael R Dispersible alcohol/cleaning wipes via topical or wet-end application of acrylamide or vinylamide/amine polymers
US7405186B2 (en) * 2005-03-25 2008-07-29 Chemsil Silicones, Inc. Lubricant compositions, condom products and methods of making same
US8030260B2 (en) 2005-03-25 2011-10-04 Chemsil Silicones, Inc Pre-shave compositions and methods of using same
US7914891B2 (en) 2005-12-28 2011-03-29 Kimberly-Clark Worldwide, Inc. Wipes including microencapsulated delivery vehicles and phase change materials
JP4711944B2 (en) * 2006-01-04 2011-06-29 株式会社アゼックス Body treatment composition and treatment method
JP2007182398A (en) * 2006-01-06 2007-07-19 Nakajima Kagaku Sangyo Kk Antiviral lubricant
US20080031833A1 (en) * 2006-03-13 2008-02-07 Oblong John E Combined energy and topical composition application for regulating the condition of mammalian skin
AU2007254340A1 (en) * 2006-05-17 2007-11-29 E. I. Du Pont De Nemours And Company Personal care compositions
US7497351B2 (en) 2006-05-30 2009-03-03 Kimberly-Clark Worldwide, Inc. Wet wipe dispensing system
US7654412B2 (en) 2006-05-30 2010-02-02 Kimberly-Clark Worldwide, Inc. Wet wipe dispensing system for dispensing warm wet wipes
US20070281008A1 (en) * 2006-06-05 2007-12-06 Lin Shun Y Personal lubricant compositions and kits for providing personal lubrication
US20090004294A1 (en) * 2006-11-07 2009-01-01 Pharmwest, Inc. Personal lubricant formulations comprising colloidal metals and methods of use
US20080128425A1 (en) * 2006-12-01 2008-06-05 Donald Rick Self-warming analgesic composition in a dual chamber bottle
US20080128426A1 (en) * 2006-12-01 2008-06-05 Donald Rick Self-warming sanitizing composition in a dual chamber bottle
US8192841B2 (en) 2006-12-14 2012-06-05 Kimberly-Clark Worldwide, Inc. Microencapsulated delivery vehicle having an aqueous core
WO2008079898A1 (en) * 2006-12-20 2008-07-03 Pharmwest, Inc. Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions
US8425923B2 (en) * 2007-02-09 2013-04-23 Dow Corning Corporation and McNeil-PPC, Inc. Lotion composition for personal use
KR101494299B1 (en) * 2007-02-09 2015-02-17 레킷트 뱅키저 (브랜즈) 리미티드 Lotion composition for personal use
US7726487B2 (en) 2007-02-09 2010-06-01 Mcneil-Ppc, Inc. Complementary personal lubricant compositions
US20090054497A1 (en) 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
US20090197892A1 (en) 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
US20090054498A1 (en) 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
CN104473966A (en) * 2007-09-28 2015-04-01 强生消费者公司 Electricity-generating particulates and the use thereof
US7924142B2 (en) 2008-06-30 2011-04-12 Kimberly-Clark Worldwide, Inc. Patterned self-warming wipe substrates
US8150525B2 (en) * 2008-08-27 2012-04-03 Johnson & Johnson Consumer Companies, Inc. Treatment of hyperhydrosis
US9456921B2 (en) 2008-11-12 2016-10-04 Chemsil Silicones, Inc. Clear, washable lubricant compositions and methods of making same
US20100012132A1 (en) * 2008-11-12 2010-01-21 Chemsil Silicones, Inc. Clear, washable lubricant compositions, and methods of making same
WO2010083239A2 (en) * 2009-01-13 2010-07-22 Truitt Edward R Iii Therapeutic modulation of vaginal epithelium boundary lubrication
US20120089232A1 (en) 2009-03-27 2012-04-12 Jennifer Hagyoung Kang Choi Medical devices with galvanic particulates
US8716203B2 (en) * 2009-10-18 2014-05-06 Eli D Ehrenpreis Water-soluble colonoscopy lubricant
BR112012011411A2 (en) * 2009-11-13 2017-12-12 Johnson & Johnson Consumer Companies Inc galvanic skin care device
KR20110091461A (en) * 2010-02-05 2011-08-11 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 Lip compositions comprising galvanic particulates
WO2011109259A1 (en) * 2010-03-01 2011-09-09 Johnson & Johnson Consumer Companies, Inc. Skin care composition having desirable bulk color
US20110236491A1 (en) * 2010-03-25 2011-09-29 Jeannette Chantalat Topical anti-inflammatory composition
US20120237612A1 (en) * 2011-03-14 2012-09-20 Lampe Jeffrey L Ultrasound Gel And Methods Of Manufacturing Same
US9949916B2 (en) 2012-10-04 2018-04-24 Church & Dwight Co., Inc. Non-irritating lubricant compositions with active sensorial agents
MX356046B (en) 2013-03-14 2018-05-03 Church & Dwight Co Inc Aqueous lubricant composition.
US10918589B2 (en) 2013-03-15 2021-02-16 John Robert Goepfert Personal-lubricating material and method for lubricant manufacture
EP3169324B1 (en) 2014-07-14 2019-05-08 Orion Biotechnology Canada Ltd. Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
US20160192901A1 (en) * 2015-01-07 2016-07-07 Thermal-Gel, Llc Warming gel system and method
US20170224824A1 (en) * 2016-02-05 2017-08-10 Guy & O'neill, Inc. Warming personal lubricant free from preservatives
US9907749B2 (en) * 2016-02-23 2018-03-06 Elle Pharmaceutical, LLC Aqueous gel composition and methods of use
US9814675B2 (en) * 2016-02-23 2017-11-14 Elle Pharmaceutical, LLC Aqueous gel composition and methods of use
JP6632442B2 (en) * 2016-03-23 2020-01-22 オカモト株式会社 Lubricants and two-material mixed lubricants
CN106137514A (en) * 2016-07-26 2016-11-23 广东诺丝科技股份有限公司 A kind of novel decorative pattern condom of tatooing
US11602582B2 (en) 2018-04-10 2023-03-14 Chemsil Silicones, Inc. Intimate care lubricant compositions and methods for making same
KR20230173817A (en) 2022-06-20 2023-12-27 주식회사 루카에이아이셀 Lubricant composition, lubricant comprising the same and preparation method thereof

Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110426A (en) * 1973-07-24 1978-08-29 Colgate-Palmolive Company Method of treating skin and hair with a self-heated cosmetic
US4232003A (en) * 1975-11-26 1980-11-04 Posthuma Albert E Synthetic physiological mucus
US4233876A (en) * 1978-07-27 1980-11-18 Thomas Leahy Method for preventing freeze-up of musical instrument valves and other movable elements
US4347237A (en) * 1981-03-02 1982-08-31 Evenstad Kenneth L Lower fatty acid glyceride high-HLB lubricating suppository and method for making and using the same
US4636520A (en) * 1984-07-16 1987-01-13 Fujisawa Pharmaceutical Co., Ltd. Antifungal composition employing pyrrolnitrin in combination with an imidazole compound
US4720507A (en) * 1984-03-05 1988-01-19 University Of Western Ontario Biological contraceptive and contraceptive technique for males
US4863725A (en) * 1982-10-27 1989-09-05 Deckner George E Novel clear oil-free moisturizer composition
US4950475A (en) * 1988-07-19 1990-08-21 Imaginative Research Associates, Inc. Novel film-forming gels with high concentrations of humectants and emollients
US4981686A (en) * 1987-05-18 1991-01-01 Hardy Robert E Personal lubricant
US5002938A (en) * 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5236609A (en) * 1989-05-03 1993-08-17 Chas F Thackray Limited Sterilizable lubricant
US5270032A (en) * 1990-10-04 1993-12-14 The Research Foundation Of State University Of New York Composition and method for the prevention and treatment of candidiasis
US5349149A (en) * 1989-10-04 1994-09-20 Castrol Limited Burmah Castrol House Dual-purpose fluid for cutting and electrical discharge machining
US5393528A (en) * 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
US5512289A (en) * 1993-07-28 1996-04-30 Johnson & Johnson Consumer Products, Inc. Spermicidal anti-viral lubricant composition and method of using same
US5513629A (en) * 1995-01-20 1996-05-07 Dura Therm Inc. Microwavable heat releasing and absorbing composition and container
US5527534A (en) * 1992-10-21 1996-06-18 Gynetech Laboratories, Ltd. Vaginal sponge delivery system
US5595980A (en) * 1993-09-29 1997-01-21 Medical College Of Hampton Roads Contraceptive compositions
US5599551A (en) * 1989-06-06 1997-02-04 Kelly; Patrick D. Genital lubricants containing zinc as an anti-viral agent
US5658583A (en) * 1995-07-28 1997-08-19 Zhang; Jie Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5709849A (en) * 1989-09-20 1998-01-20 Shiseido Company Ltd Suppressing stickiness to skin of cosmetic composition
US5840744A (en) * 1988-01-15 1998-11-24 Minnesota Mining And Manufacturing Co. Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5885591A (en) * 1996-07-02 1999-03-23 Johnson & Johnson Consumer Products, Inc. Personal lubricant compositions
US5895658A (en) * 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
US5902593A (en) * 1997-10-01 1999-05-11 Kent; Frances B. Topically applied personal lubricant containing benzalkonium chloride as the active ingredient
US5980924A (en) * 1997-04-09 1999-11-09 Kao Corporation Skin cleansing sheet
US5980875A (en) * 1996-04-12 1999-11-09 Mousa; Mahmoud A. Honey preparations
US6007846A (en) * 1997-05-16 1999-12-28 Townley Jewelry, Inc. Scented body gel having particulate matter in the form of glitter with predetermined shapes
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
US6019782A (en) * 1996-12-31 2000-02-01 The Procter & Gamble Company Disposable thermal body pad
US6060077A (en) * 1995-10-05 2000-05-09 Laboratoire Innothera, Societe Anonyme Unit galenical formulation for local hormonotherapy of vaginal dryness
US6153208A (en) * 1997-09-12 2000-11-28 The Procter & Gamble Company Cleansing and conditioning article for skin or hair
US6171604B1 (en) * 1996-04-12 2001-01-09 Mahmoud A. Mousa Honey preparations
US6190680B1 (en) * 1998-04-01 2001-02-20 The Nisshin Oil Mills, Ltd. Oily composition and process for producing the same
US6221814B1 (en) * 1998-04-21 2001-04-24 Shin-Etsu Handotai Co., Ltd. Aqueous compositions, aqueous cutting fluid using the same, method for preparation thereof, and cutting method using the cutting fluid
US6303108B1 (en) * 1998-06-15 2001-10-16 L'oreal Solid warming pulverulent composition to be hydrated for caring for or cleaning the skin
US6328991B1 (en) * 1992-10-21 2001-12-11 John Myhling Composition and method for prevention of sexually transmitted diseases, including aids
US6338855B1 (en) * 1996-10-25 2002-01-15 The Procter & Gamble Company Cleansing articles for skin and/or hair which also deposit skin care actives
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020103414A1 (en) * 2000-12-05 2002-08-01 Harrison Michael J. Condom with male genital desensitizer lubricant
US6531171B2 (en) * 2001-07-03 2003-03-11 Nutricia Usa, Inc. Food products containing betaine
US20030092754A1 (en) * 1999-07-16 2003-05-15 Nishizumi Nishimuta External preparation for skin diseases containing nitroimidazole
US6641825B2 (en) * 2000-03-01 2003-11-04 Henkel Kommanditgesellschaft Auf Aktien Skin cleansing gel having a heating effect
US6664296B1 (en) * 1994-12-22 2003-12-16 Laboratoire Innothera Societe Anonyme Unit galenical formulation for vaginal use as a local contraceptive and/or to combat sexually-transmitted diseases and/or HIV
US6706674B2 (en) * 2001-01-17 2004-03-16 The Andrew Jergens Company Nonaqueous hair styling composition and method of use
US6706574B2 (en) * 1999-11-04 2004-03-16 Raytheon Company Field effect transistor and method for making the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US92754A (en) * 1869-07-20 Improvement in dust-pan
EP0027730A3 (en) 1979-10-17 1981-10-21 Johnson Company, Limited Cosmetic composition generating heat upon use
IE53610B1 (en) * 1981-12-14 1988-12-21 Merck & Co Inc Waterless thixotropic composition
JPS63130541A (en) * 1986-11-18 1988-06-02 Sunstar Inc Antimicrobial composition
JPH02264723A (en) * 1989-04-06 1990-10-29 Taisho Pharmaceut Co Ltd Antifungal agent
JPH02311408A (en) 1989-05-25 1990-12-27 Mandamu:Kk Gel-like composition for skin
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
FR2657523A1 (en) * 1990-01-29 1991-08-02 Oreal REDUCING COSMETIC COMPOSITION FOR THE PERMANENT DEFORMATION OF HAIR BASED ON AN ESTER OF THIOGLYCOLIC ACID AND N-ACETYLCYSTEAMINE AND METHOD FOR THE IMPLEMENTATION THEREOF
NZ235054A (en) 1990-08-24 1992-11-25 Bristol Myers Squibb Co Gel formulation comprising imidazole antifungal agent and a 17-ester steroid anti-inflammatory agent with a co-solvent system and a gelling agent
GR1002418B (en) 1992-07-29 1996-08-21 Johnson & Johnson Consumer Products Inc. Bioactive treatment compositions and methods of use.
JPH06287133A (en) * 1993-03-31 1994-10-11 Sunstar Inc Non-aqueous pasty composition for oral cavity application
DE4327360A1 (en) * 1993-08-14 1995-02-16 Basf Ag Deicing agents or anti-icing agents for aircraft
ES2074030B1 (en) 1994-01-31 1996-02-01 S A L V A T Lab Sa CARRIER, SELF-HEATING AND APPLICABLE COMPOSITIONS IN THERAPEUTICS BY VIA TOPICA.
FR2739559B1 (en) 1995-10-05 1997-11-28 Innothera Lab Sa GEL FOR LOCAL HORMONOTHERAPY OF VAGINAL DROUGHT
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
JP2001503058A (en) 1996-10-25 2001-03-06 ザ、プロクター、エンド、ギャンブル、カンパニー Cleaning products
DE69738046D1 (en) 1996-10-29 2007-10-04 Grant Ind Inc PRECIPITATED RUBBER-LIKE SILICON GEL WITH INCREASED OIL COMPATIBILITY AND ITS SYNTHESIS
DE19781197D2 (en) 1996-10-31 2000-07-13 Notax Holding Ges M B H Wien Use of polyethylene glycol 9 nonylphenyl ether
CA2306837C (en) * 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
CA2309260C (en) 1997-12-03 2011-09-13 E.I. Du Pont De Nemours And Company 2,4-substituted pyrimidines and their use in herbicidal compositions
GB2331924A (en) 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
US6036857A (en) 1998-02-20 2000-03-14 Florida State University Research Foundation, Inc. Apparatus for continuous magnetic separation of components from a mixture
JP2000109414A (en) * 1998-10-01 2000-04-18 Kao Corp Cosmetic
CN1065137C (en) * 1998-11-13 2001-05-02 秦杏生 Liniment made of traditional Chinese medicine for treating pharyngitis, and prepn. method therefor
US6238683B1 (en) * 1998-12-04 2001-05-29 Johnson & Johnson Consumer Companies, Inc. Anhydrous topical skin preparations
US6139848A (en) * 1999-02-12 2000-10-31 Mcneil-Ppc, Inc. Personal lubricant compositions
JP3660560B2 (en) 2000-05-23 2005-06-15 株式会社マンダム Gel cosmetic
RU2180556C2 (en) 2000-05-26 2002-03-20 Высоков Виктор Игоревич Gel-lubricant (variants)
US20030017207A1 (en) 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US7005408B2 (en) * 2002-05-01 2006-02-28 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US20040103414A1 (en) * 2002-11-27 2004-05-27 Vomlehn David M. Method and apparatus for interprocess communications

Patent Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110426A (en) * 1973-07-24 1978-08-29 Colgate-Palmolive Company Method of treating skin and hair with a self-heated cosmetic
US4232003A (en) * 1975-11-26 1980-11-04 Posthuma Albert E Synthetic physiological mucus
US4233876A (en) * 1978-07-27 1980-11-18 Thomas Leahy Method for preventing freeze-up of musical instrument valves and other movable elements
US4347237A (en) * 1981-03-02 1982-08-31 Evenstad Kenneth L Lower fatty acid glyceride high-HLB lubricating suppository and method for making and using the same
US4863725A (en) * 1982-10-27 1989-09-05 Deckner George E Novel clear oil-free moisturizer composition
US4720507A (en) * 1984-03-05 1988-01-19 University Of Western Ontario Biological contraceptive and contraceptive technique for males
US4636520A (en) * 1984-07-16 1987-01-13 Fujisawa Pharmaceutical Co., Ltd. Antifungal composition employing pyrrolnitrin in combination with an imidazole compound
US4981686A (en) * 1987-05-18 1991-01-01 Hardy Robert E Personal lubricant
US5840744A (en) * 1988-01-15 1998-11-24 Minnesota Mining And Manufacturing Co. Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5002938A (en) * 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
US4950475A (en) * 1988-07-19 1990-08-21 Imaginative Research Associates, Inc. Novel film-forming gels with high concentrations of humectants and emollients
US5236609A (en) * 1989-05-03 1993-08-17 Chas F Thackray Limited Sterilizable lubricant
US5599551A (en) * 1989-06-06 1997-02-04 Kelly; Patrick D. Genital lubricants containing zinc as an anti-viral agent
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5709849A (en) * 1989-09-20 1998-01-20 Shiseido Company Ltd Suppressing stickiness to skin of cosmetic composition
US5349149A (en) * 1989-10-04 1994-09-20 Castrol Limited Burmah Castrol House Dual-purpose fluid for cutting and electrical discharge machining
US5270032A (en) * 1990-10-04 1993-12-14 The Research Foundation Of State University Of New York Composition and method for the prevention and treatment of candidiasis
US5393528A (en) * 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
US5529782A (en) * 1992-05-07 1996-06-25 Staab; Robert Dissolvable device for contraception or delivery of medication
US6328991B1 (en) * 1992-10-21 2001-12-11 John Myhling Composition and method for prevention of sexually transmitted diseases, including aids
US5527534A (en) * 1992-10-21 1996-06-18 Gynetech Laboratories, Ltd. Vaginal sponge delivery system
US5512289A (en) * 1993-07-28 1996-04-30 Johnson & Johnson Consumer Products, Inc. Spermicidal anti-viral lubricant composition and method of using same
US5595980A (en) * 1993-09-29 1997-01-21 Medical College Of Hampton Roads Contraceptive compositions
US6664296B1 (en) * 1994-12-22 2003-12-16 Laboratoire Innothera Societe Anonyme Unit galenical formulation for vaginal use as a local contraceptive and/or to combat sexually-transmitted diseases and/or HIV
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5513629A (en) * 1995-01-20 1996-05-07 Dura Therm Inc. Microwavable heat releasing and absorbing composition and container
US5658583A (en) * 1995-07-28 1997-08-19 Zhang; Jie Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals
US6060077A (en) * 1995-10-05 2000-05-09 Laboratoire Innothera, Societe Anonyme Unit galenical formulation for local hormonotherapy of vaginal dryness
US5980875A (en) * 1996-04-12 1999-11-09 Mousa; Mahmoud A. Honey preparations
US6171604B1 (en) * 1996-04-12 2001-01-09 Mahmoud A. Mousa Honey preparations
US5885591A (en) * 1996-07-02 1999-03-23 Johnson & Johnson Consumer Products, Inc. Personal lubricant compositions
US6338855B1 (en) * 1996-10-25 2002-01-15 The Procter & Gamble Company Cleansing articles for skin and/or hair which also deposit skin care actives
US6019782A (en) * 1996-12-31 2000-02-01 The Procter & Gamble Company Disposable thermal body pad
US5980924A (en) * 1997-04-09 1999-11-09 Kao Corporation Skin cleansing sheet
US6007846A (en) * 1997-05-16 1999-12-28 Townley Jewelry, Inc. Scented body gel having particulate matter in the form of glitter with predetermined shapes
US6153208A (en) * 1997-09-12 2000-11-28 The Procter & Gamble Company Cleansing and conditioning article for skin or hair
US5895658A (en) * 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
US5902593A (en) * 1997-10-01 1999-05-11 Kent; Frances B. Topically applied personal lubricant containing benzalkonium chloride as the active ingredient
US5976561A (en) * 1997-10-01 1999-11-02 Kent; Frances B. Topically applied sensitizing gel and method of using the same
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6190680B1 (en) * 1998-04-01 2001-02-20 The Nisshin Oil Mills, Ltd. Oily composition and process for producing the same
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
US6221814B1 (en) * 1998-04-21 2001-04-24 Shin-Etsu Handotai Co., Ltd. Aqueous compositions, aqueous cutting fluid using the same, method for preparation thereof, and cutting method using the cutting fluid
US6303108B1 (en) * 1998-06-15 2001-10-16 L'oreal Solid warming pulverulent composition to be hydrated for caring for or cleaning the skin
US20030092754A1 (en) * 1999-07-16 2003-05-15 Nishizumi Nishimuta External preparation for skin diseases containing nitroimidazole
US6706574B2 (en) * 1999-11-04 2004-03-16 Raytheon Company Field effect transistor and method for making the same
US6641825B2 (en) * 2000-03-01 2003-11-04 Henkel Kommanditgesellschaft Auf Aktien Skin cleansing gel having a heating effect
US20020103414A1 (en) * 2000-12-05 2002-08-01 Harrison Michael J. Condom with male genital desensitizer lubricant
US6706674B2 (en) * 2001-01-17 2004-03-16 The Andrew Jergens Company Nonaqueous hair styling composition and method of use
US6531171B2 (en) * 2001-07-03 2003-03-11 Nutricia Usa, Inc. Food products containing betaine

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188528A1 (en) * 2005-02-23 2006-08-24 Ansell Healthcare Products Llc Spreadable warming lubricant
US20060189493A1 (en) * 2005-02-23 2006-08-24 Ansell Healthcare Products Llc Thickened spreadable warming lubricant
US7709428B2 (en) 2005-02-23 2010-05-04 Ansell Healthcare Products Llc Thickened spreadable warming lubricant
US20100160457A1 (en) * 2005-02-23 2010-06-24 Ansell Healthcare Products Llc Thickened Spreadable Warming Lubricant
US20100186751A1 (en) * 2005-02-23 2010-07-29 Ansell Healthcare Products Llc Spreadable Warming Lubricant
US8193134B2 (en) 2005-02-23 2012-06-05 Ansell Healthcare Products Llc Thickened spreadable warming lubricant
US8303969B2 (en) 2005-02-23 2012-11-06 Ansell Healthcare Products Llc Spreadable warming lubricant
US20070059266A1 (en) * 2005-09-12 2007-03-15 Nawaz Ahmad Sprayable personal lubricant
US20070059250A1 (en) * 2005-09-12 2007-03-15 Nawaz Ahmad Sprayable personal lubricant
US7851419B2 (en) 2005-09-12 2010-12-14 Nawaz Ahmad Substantially anhydrous sprayable personal lubricant
US20090107513A1 (en) * 2007-10-26 2009-04-30 Ansell Healthcare Products Llc Condom With Multifunctional Coating
US8770201B2 (en) 2007-10-26 2014-07-08 Glycobiosciences Inc. Condom with multifunctional coating

Also Published As

Publication number Publication date
ES2330096T3 (en) 2009-12-04
US7758887B2 (en) 2010-07-20
BR0309769A (en) 2005-03-22
AU2009202927A1 (en) 2009-08-06
JP4712377B2 (en) 2011-06-29
AU2009202931A1 (en) 2009-08-06
JP4738809B2 (en) 2011-08-03
RU2004131861A (en) 2005-05-27
US20030207772A1 (en) 2003-11-06
US20030232090A1 (en) 2003-12-18
BRPI0309769B8 (en) 2021-05-25
JP2011046737A (en) 2011-03-10
EP2108359A1 (en) 2009-10-14
US7285517B2 (en) 2007-10-23
KR20110125660A (en) 2011-11-21
EP2108359B1 (en) 2017-06-21
KR101126088B1 (en) 2012-03-30
EP1499290B1 (en) 2009-07-22
AU2009202895A1 (en) 2009-08-06
KR20050062465A (en) 2005-06-23
JP2005531541A (en) 2005-10-20
DE60328475D1 (en) 2009-09-03
BRPI0309769B1 (en) 2015-12-29
US7005408B2 (en) 2006-02-28
EP1499290A1 (en) 2005-01-26
WO2003092651A1 (en) 2003-11-13
AU2011200395A1 (en) 2011-02-17
JP2005530747A (en) 2005-10-13
CA2484275A1 (en) 2003-11-13
AU2009202895B2 (en) 2012-06-28
RU2344808C2 (en) 2009-01-27
US20030211161A1 (en) 2003-11-13
AU2003225242A1 (en) 2003-11-17
NZ588194A (en) 2010-11-26
MXPA04010887A (en) 2005-07-14
ES2308045T3 (en) 2008-12-01
CA2484275C (en) 2011-03-22
ES2640745T3 (en) 2017-11-06

Similar Documents

Publication Publication Date Title
US7005408B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US7417013B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US20070287714A1 (en) Warming and Nonirritating Lubricant Compositions and Method of Comparing Irritation
US7658941B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US20040167039A1 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US7695730B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US20040185065A1 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
RU2288700C2 (en) Warming and non-irritating anhydrous lubricating compositions
US20090053163A1 (en) Warming and nonirritating lubricant compositions and method of comparing irritation

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION